Autoimmune Disorders

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn’s disease.

Primary disease category:

Digestive System

Secondary disease category(ies):

Autoimmune Disorders

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn disease.

Primary disease category:

Digestive System

Secondary disease category(ies):

Autoimmune Disorders

A randomized, double-blind, placebo-controlled, parallel-group, phase 2 study evaluating the efficacy and safety of Baricitinib in patients with Systemic Lupus Erythematosus (SLE)

JAHH is a Phase 2, multicenter, randomized, double-blind, placebo controlled, outpatient, 24-week study evaluating the efficacy and safety of baricitinib 4-mg and 2-mg in patients with SLE receiving standard therapy. Approximately 300 patients will be randomized 1:1:1 to receive baricitinib 4-mg daily, baricitinib 2-mg daily, or placebo (100 patients per treatment group).

Primary disease category:

Autoimmune Disorders